INR-102

N/A

Report date: 2025/09/19 16:47:30
NME

Base Information

Drug NameINR-102
Drug Alias NameINR102INR-102[177Lu]Lu-PSMA-137
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionRadionuclide imaging enhancersPositron-emission tomography enhancersProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesYunhe Pharmaceutical (Tianjin) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesThe First Affiliated Hospital Of Beijing UniversityYunhe Pharmaceutical (Tianjin) Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A